Bydgoszcz

• A trial to learn if rilvegostomig with chemotherapy given after surgery is safe in people with biliary tract cancer and works to delay when … Ended recruitment
  2023-506054-20-00 5 2024-06-05 Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic chol
• A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-sm … Ended recruitment
  2023-508359-38-00 5 2024-06-05 Early-stage Non-squamous Non-small Cell Lung Cancer
• A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intraves … Ended recruitment
  2023-507685-10-00 5 2024-05-30 High-Risk Non-muscle-invasive Bladder Cancer
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended recruitment
  2023-503231-17-00 5 2024-04-26 Unresectable Pleural Mesothelioma
• A clinical study of V940 treatment and pembrolizumab in people with bladder cancer (V940-005) Ended recruitment
  2023-505658-17-00 4 2024-04-16 Muscle-invasive Urothelial Carcinoma
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit … Ended recruitment
  2023-505928-59-00 5 2024-04-15 Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
• Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil … Ended recruitment
  2023-506029-12-00 5 2024-04-03 Migraine
• A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim … Ended recruitment
  2023-506183-13-00 4 2024-03-29 Alzheimer’s Disease
• ATHENA: A research study looking into how ziltivekimab works compared to placebo in people with heart failure and inflammation Ended recruitment
  2023-506988-34-00 5 2024-03-27 Heart failure with mildly reduced or preserved ejection fraction and s
• A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults Ended recruitment
  2023-504827-17-00 5 2024-03-18 Chronic migraine
• A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults Ended recruitment
  2023-504839-40-00 5 2024-03-18 Episodic Migraine
• Patient Preference Study of SC Pembrolizumab versus IV Pembrolizumab with hyaluronidase (MK-3475A) in multiple cancer types Ended recruitment
  2023-506017-22-00 4 2024-02-16 Melanoma, Renal Cell Carcinoma, Non-small cell lung cancer
• A study to evaluate the efficacy, safety, and tolerability of using an oral once-daily 2 drug regimen compared to an oral once-daily 3 drug … Ended recruitment
  2023-504993-40-00 5 2024-02-14 Human immunodeficiency virus (HIV)
• A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression Ended recruitment
  2023-505268-12-00 5 2024-02-09 Treatment-resistant depression
• Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine … Ended recruitment
  2022-501172-25-00 5 2024-01-17 Chronic and Episodic Migraine
• A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended recruitment
  2022-502442-27-00 5 2024-01-08 Obesity
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thy … Ended recruitment
  2023-503669-50-00 5 2023-12-27 Moderate-to-Severe Thyroid Eye Disease
• A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Par … Ended recruitment
  2022-501396-62-00 5 2023-12-12 Relapsed Refractory Multiple Myeloma
• A Study of Susceptibility to Baloxavir Marboxil in Patients with Influenza and its transmission to their household contacts Ended recruitment
  2023-504672-22-00 5 2023-11-24 Influenza
• Determine effectiveness of Anifrolumab In Systemic sclerosis Ended recruitment
  2023-505976-31-00 5 2023-11-24 Systemic Sclerosis (SSc) presenting with Limited or Diffuse Cutaneous
• Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended recruitment
  2023-503265-27-00 5 2023-11-23 Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
• A Study of an Intermittent ADT Approach with Apalutamide Monotherapy in Participants with mCSPC Ended recruitment
  2022-502686-24-00 5 2023-11-22 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended recruitment
  2023-503655-10-00 5 2023-11-20 Systemic Lupus Erythematosus (SLE).

Showing 385–408 of 707 trials